{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:55Z","timestamp":1786997935876,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.vaccine.2010.11.064","type":"journal-article","created":{"date-parts":[[2010,12,4]],"date-time":"2010-12-04T04:31:07Z","timestamp":1291437067000},"page":"1072-1081","source":"Crossref","is-referenced-by-count":48,"title":["Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1"],"prefix":"10.1016","volume":"29","author":[{"given":"Brunella","family":"Brunelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Del Tordello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Biolchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bambini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Comanducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Muzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia M.","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Serruto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"June (Suppl. 2)","key":"10.1016\/j.vaccine.2010.11.064_bib0005","doi-asserted-by":"crossref","first-page":"B71","DOI":"10.1016\/j.vaccine.2009.04.070","article-title":"Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis","volume":"27","author":"Stephens","year":"2009","journal-title":"Vaccine"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2010.11.064_bib0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1586\/erv.09.18","article-title":"Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy","volume":"8","author":"Pace","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2010.11.064_bib0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.inf.0000202065.03366.0c","article-title":"Population-based analysis of meningococcal disease mortality in the United States: 1990\u20132002","volume":"25","author":"Sharip","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2010.11.064_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1574-6976.2006.00060.x","article-title":"A surveillance network for meningococcal disease in Europe","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"issue":"August (8346)","key":"10.1016\/j.vaccine.2010.11.064_bib0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"issue":"June (Suppl. 2)","key":"10.1016\/j.vaccine.2010.11.064_bib0030","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"issue":"April (16)","key":"10.1016\/j.vaccine.2010.11.064_bib0035","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis","volume":"362","author":"Tan","year":"2010","journal-title":"N Engl J Med"},{"issue":"June (Suppl. 2)","key":"10.1016\/j.vaccine.2010.11.064_bib0040","doi-asserted-by":"crossref","first-page":"B42","DOI":"10.1016\/j.vaccine.2009.05.001","article-title":"Meningococcal protein antigens and vaccines","volume":"27","author":"Feavers","year":"2009","journal-title":"Vaccine"},{"issue":"March (5459)","key":"10.1016\/j.vaccine.2010.11.064_bib0045","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2010.11.064_bib0050","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2958.2004.04423.x","article-title":"Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells","volume":"55","author":"Capecchi","year":"2005","journal-title":"Mol Microbiol"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2010.11.064_bib0055","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"J Exp Med"},{"issue":"February (8)","key":"10.1016\/j.vaccine.2010.11.064_bib0060","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","author":"Serruto","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2010.11.064_bib0065","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2010.11.064_bib0070","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.01071-08","article-title":"Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37","volume":"77","author":"Seib","year":"2009","journal-title":"Infect Immun"},{"issue":"July (29)","key":"10.1016\/j.vaccine.2010.11.064_bib0075","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"March (17\u201318)","key":"10.1016\/j.vaccine.2010.11.064_bib0080","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2010.11.064_bib0085","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/CVI.00039-07","article-title":"Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines","volume":"14","author":"Wedege","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2010.11.064_bib0090","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"issue":"July (37)","key":"10.1016\/j.vaccine.2010.11.064_bib0095","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"issue":"June (Suppl. 2)","key":"10.1016\/j.vaccine.2010.11.064_bib0100","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"issue":"June (24)","key":"10.1016\/j.vaccine.2010.11.064_bib0105","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization\u2014international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2010.11.064_bib0110","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2010.11.064_bib0115","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/nar\/gkh340","article-title":"MUSCLE: multiple sequence alignment with high accuracy and high throughput","volume":"32","author":"Edgar","year":"2004","journal-title":"Nucleic Acids Res"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2010.11.064_bib0120","first-page":"275","article-title":"The rapid generation of mutation data matrices from protein sequences","volume":"8","author":"Jones","year":"1992","journal-title":"Comput Appl Biosci"},{"issue":"July (4)","key":"10.1016\/j.vaccine.2010.11.064_bib0125","first-page":"406","article-title":"The neighbor-joining method: a new method for reconstructing phylogenetic trees","volume":"4","author":"Saitou","year":"1987","journal-title":"Mol Biol Evol"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2010.11.064_bib0130","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/molbev\/msm092","article-title":"MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0","volume":"24","author":"Tamura","year":"2007","journal-title":"Mol Biol Evol"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2010.11.064_bib0135","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1128\/JB.187.10.3421-3430.2005","article-title":"CrgA is an inducible LysR-type regulator of Neisseria meningitidis, acting both as a repressor and as an activator of gene transcription","volume":"187","author":"Ieva","year":"2005","journal-title":"J Bacteriol"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2010.11.064_bib0140","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.4049\/jimmunol.160.10.5028","article-title":"Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid","volume":"160","author":"Granoff","year":"1998","journal-title":"J Immunol"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2010.11.064_bib0145","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/CDLI.12.8.970-976.2005","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"issue":"May","key":"10.1016\/j.vaccine.2010.11.064_bib0150","article-title":"Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus","author":"Giuliani","year":"2010","journal-title":"Vaccine"},{"issue":"May (21)","key":"10.1016\/j.vaccine.2010.11.064_bib0155","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.vaccine.2009.02.098","article-title":"Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus","volume":"27","author":"Bambini","year":"2009","journal-title":"Vaccine"},{"issue":"March (10)","key":"10.1016\/j.vaccine.2010.11.064_bib0160","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.vaccine.2008.12.052","article-title":"Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease","volume":"27","author":"Jacobsson","year":"2009","journal-title":"Vaccine"},{"issue":"April (6)","key":"10.1016\/j.vaccine.2010.11.064_bib0165","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterisation of fHbp, nhba (gna2132), nadA, porA and Sequence Type in group B meningococcal case isolates collected in England and Wales during January 2008, and potential coverage of an investigational group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2010.11.064_bib0170","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1128\/CVI.00195-07","article-title":"Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay","volume":"14","author":"Findlow","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2010.11.064_bib0175","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/JB.01308-09","article-title":"Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter","volume":"192","author":"Oriente","year":"2010","journal-title":"J Bacteriol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2010.11.064_bib0180","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1128\/IAI.69.6.3762-3771.2001","article-title":"Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B","volume":"69","author":"Moe","year":"2001","journal-title":"Infection and immunity"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2010.11.064_bib0185","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1128\/IAI.67.11.5664-5675.1999","article-title":"Differences in surface expression of NspA among Neisseria meningitidis group B strains","volume":"67","author":"Moe","year":"1999","journal-title":"Infect Immun"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2010.11.064_bib0190","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/IAI.62.10.4419-4424.1994","article-title":"Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy","volume":"62","author":"Milagres","year":"1994","journal-title":"Infect Immun"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2010.11.064_bib0195","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.vaccine.2006.07.016","article-title":"Shielding of immunogenic domains in Neisseria meningitidis FrpB (FetA) by the major variable region","volume":"25","author":"Kortekaas","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.11.064_bib0200","series-title":"28th ESPID Meeting","article-title":"Phase III formulation development of recombinant meningococcal B vaccine (rMenB) containing fHbp, NHBA, NadA, and New Zealand strain (NZ98\/254) outer membrane vesicles (OMV)","author":"Dull","year":"2010"},{"issue":"October","key":"10.1016\/j.vaccine.2010.11.064_bib0205","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10017081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10017081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T16:01:45Z","timestamp":1711987305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10017081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0264410X10017081"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.11.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}